Disease diversity and FLT3 mutations

被引：5
|
作者：
Smith, Catherine Choy [1 ]
机构：
[1] Univ Calif San Francisco, Dept Med, Div Hematol Oncol, San Francisco, CA 94143 USA
来源：
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA | 2013年 / 110卷 / 52期
关键词：
ACUTE MYELOID-LEUKEMIA; INTERNAL TANDEM DUPLICATION; GASTROINTESTINAL STROMAL TUMORS; KINASE DOMAIN MUTATIONS; THERAPEUTIC TARGET; ITD MUTATIONS; RESISTANCE; VALIDATION; ACTIVATION; GEFITINIB;
D O I：
10.1073/pnas.1320579110
中图分类号：
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
引用
收藏
页码：20860 / 20861
页数：2
相关论文
共 50 条
  • [31] Gilteritinib: potent targeting of FLT3 mutations in AML
    Levis, Mark
    Perl, Alexander E.
    BLOOD ADVANCES, 2020, 4 (06) : 1178 - 1191
  • [32] FLT3 mutations in canine acute lymphocytic leukemia
    Suter, Steven E.
    Small, George W.
    Seiser, Eric L.
    Thomas, Rachael
    Breen, Matthew
    Richards, Kristy L.
    BMC CANCER, 2011, 11
  • [33] FLT3 Mutations in Myeloproliferative Neoplasms: The Beaumont Experience
    Williams, Lindsay
    Crisan, Domnita
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2012, 138 (03) : 464 - 464
  • [34] Resistance to Selective FLT3 Inhibitors, Driven by FLT3 Ligand and FLT3 Point Mutations, Can Be Overcome with the Dual FLT3-Aurora Kinase Inhibitor CCT241736
    Moore, Andrew S.
    Faisal, Amir
    Bavetsias, Vassilios
    de Castro, David Gonzalez
    Sun, Chongbo
    Atrash, Butrus
    Valenti, Melanie
    Brandon, Alexis de Haven
    Avery, Sian
    Pearson, Andrew D. J.
    Workman, Paul
    Blagg, Julian
    Raynaud, Florence I.
    Eccles, Suzanne A.
    Linardopoulos, Spiros
    BLOOD, 2011, 118 (21) : 1490 - 1490
  • [35] Combinatorial treatment with menin and FLT3 inhibitors induces complete remission in AML models with activating FLT3 mutations
    Miao, Hongzhi
    Kim, EunGi
    Chen, Dong
    Purohit, Trupta
    Kempinska, Katarzyna
    Ropa, James
    Klossowski, Szymon
    Trotman, Winifred
    Danet-Desnoyers, Gwenn
    Cierpicki, Tomasz
    Grembecka, Jolanta
    BLOOD, 2020, 136 (25) : 2958 - +
  • [36] Discovery of a Potent FLT3 Inhibitor (LT-850-166) with the Capacity of Overcoming a Variety of FLT3 Mutations
    Wang, Zhijie
    Cai, Jiongheng
    Ren, Jiwei
    Chen, Yun
    Wu, Yingli
    Cheng, Jie
    Jia, Kun
    Huang, Fei
    Cheng, Zitian
    Sheng, Tiancheng
    Song, Shiyu
    Heng, Hao
    Zhu, Yifan
    Tang, Weifang
    Li, Hongmei
    Lu, Tao
    Chen, Yadong
    Lu, Shuai
    JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (19) : 14664 - 14701
  • [37] A novel FLT3 inhibitor FI-700 selectively suppresses the growth of leukemia cells with FLT3 mutations
    Kiyoi, Hitoshi
    Shiotsu, Yukimasa
    Ozeki, Kazutaka
    Yamaji, Satomi
    Kosugi, Hiroshi
    Umehara, Hiroshi
    Shimizu, Makiko
    Arai, Hitoshi
    Ishii, Kenichi
    Akinaga, Shiro
    Naoe, Tomoki
    CLINICAL CANCER RESEARCH, 2007, 13 (15) : 4575 - 4582
  • [38] Further activation of FLT3 mutants by FLT3 ligand
    R Zheng
    E Bailey
    B Nguyen
    X Yang
    O Piloto
    M Levis
    D Small
    Oncogene, 2011, 30 : 4004 - 4014
  • [39] Further activation of FLT3 mutants by FLT3 ligand
    Zheng, R.
    Bailey, E.
    Nguyen, B.
    Yang, X.
    Piloto, O.
    Levis, M.
    Small, D.
    ONCOGENE, 2011, 30 (38) : 4004 - 4014
  • [40] The Irreversible FLT3 Inhibitor FF-10101 Is Active Against a Diversity of FLT3 Inhibitor Resistance Mechanisms
    Ferng, Timothy T.
    Terada, Daisuke
    Ando, Makoto
    Tarver, Theodore C.
    Chaudhary, Fihr
    Lin, Kimberly C.
    Logan, Aaron C.
    Smith, Catherine C.
    MOLECULAR CANCER THERAPEUTICS, 2022, 21 (05) : 844 - 854
12345